阿尔茨海默病手术被叫停，医学创新落地当慎之又慎

Core Viewpoint - The National Health Commission has banned the use of lymphatic-venous anastomosis (LVA) for treating Alzheimer's disease due to a lack of clinical evidence supporting its safety and efficacy [1][2][4] Group 1: Regulatory Actions - The National Health Commission issued notifications prohibiting the use of LVA for Alzheimer's treatment and also banned the use of jejunoileal anastomosis for type 2 diabetes [1] - The decision was based on evaluations that found insufficient clinical evidence and a lack of clear indications and contraindications for the LVA procedure [2] Group 2: Medical Innovation Concerns - The application of LVA for Alzheimer's treatment is considered an off-label use, lacking theoretical and clinical trial support, which raises concerns about the safety of patients [3] - There is a growing trend of medical institutions promoting unverified technologies as innovative treatments, which can mislead patients and exploit their desperation for effective therapies [3][4] Group 3: Ethical and Research Standards - The use of unproven techniques in clinical settings blurs the line between clinical research and clinical application, leading to potential patient exploitation [2] - Ethical guidelines require that clinical research undergoes proper design and informed consent, which many institutions have failed to adhere to in the case of LVA [2][3]